IP Library Granted Patent US 10,194,833
Granted Patent B2
US 10,194,833 · App. 14/720,447 · Granted Feb 5, 2019

Method and apparatus for non-invasive detection of conditions such as lung cancer

Inventor: John Cormier (Dieppe, CA)
Assignee: Picomole Instruments Inc.
A61B5/082A61B5/097G01N21/3504G01N33/497A61B5/7271G01N2033/4975G01N2800/12G01N2800/7028
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,194,833
App. No.
14/720,447
Granted
Feb 5, 2019
Kind
B2
Abstract

A method of determining whether a subject is likely to have a condition includes measuring concentration levels of a plurality of target biomarkers in a sample obtained from the subject; comparing the measured concentration levels to respective reference concentration levels; in the event that the measured concentration level of at least one of the target biomarkers is less than its respective reference concentration level, and the measured concentration level of at least one of the target biomarkers is greater than its respective reference concentration level, providing an indication that the subject is likely to have the condition, and otherwise: providing an indication that the subject is unlikely to have the condition.

Claims (18)

1. An automated computer-implemented method of rapidly detecting a combination of up- and down-regulated target biomarkers in a breath sample of an individual, the combination of target biomarkers being indicative of the presence of lung cancer, the method comprising:

providing a computer processor operative to determine whether the individual is likely to have lung cancer based on a concentration level for each of the target biomarkers, wherein the target biomarkers consist of isoprene, furan, ethyl alcohol, toluene and m-Cresol,

obtaining the breath sample from the individual,

emitting infrared light through the sample and measuring the infrared light absorbance values of the sample to detect the presence of the target biomarkers, the light absorbance values being indicative of the concentration level for each of the detected target biomarkers,

determining which of the detected target biomarkers has a concentration level that is less than a respective threshold reference infrared absorption value and which of the detected target biomarkers has a concentration level that is greater than its respective threshold reference value,

where the combination of target biomarkers having lower concentration levels and target biomarkers having greater concentration levels is indicative of the presence of lung cancer, and

displaying, at the computer processor, the indicated presence of lung cancer to the individual.

2. The method of claim 1 , wherein the target biomarkers that are down-regulated are isoprene and furan.

3. The method of claim 1 , wherein the target biomarkers that are up-regulated are ethyl alcohol, toluene, and m-Cresol.

4. The method of claim 1 , wherein the combination indicative of the presence of lung cancer consists of the detected concentration levels of isoprene and furan being less than their respective threshold reference values, and the detected concentration levels of ethyl alcohol, toluene and m-Cresol being greater than their respective threshold reference values.

5. The method of claim 1 , wherein the infrared light is emitted in a plurality of pulsed, discrete monochromatic frequencies.

6. An automated computer-implemented method of rapidly detecting a combination of up- and down-regulated target biomarkers in a breath sample of an individual, the combination of target biomarkers being indicative of the presence of lung cancer, the method comprising:

providing a computer processor operative to determine whether the individual is likely to have lung cancer based on a concentration level for each of the target biomarkers, wherein the target biomarkers consist of isoprene, furan, ethyl alcohol, toluene and m-Cresol,

obtaining the breath sample from the individual,

emitting infrared light through the sample and measuring the infrared light absorbance values of the sample to detect the presence of the target biomarkers, the light absorbance values being indicative of the concentration level for each of the detected target biomarkers,

determining which of the detected target biomarkers has a concentration level that is less than a respective threshold reference infrared absorption value and which of the detected target biomarkers has a concentration level that is greater than its respective threshold reference value, and

displaying, at the computer processor, the indicated presence of lung cancer to the individual,

wherein the combination indicative of the presence of lung cancer consists of the detected concentration levels of isoprene and furan being less than their respective threshold reference values, and the detected concentration levels of ethyl alcohol, toluene and m-Cresol being greater than their respective threshold reference values.

Assignments (4)
CHANGE OF NAME Recorded Jul 2, 2024
From: PICOMOLE INC.
To: BREATHE BIOMEDICAL INC.
Reel/Frame 068117/0835 →
CHANGE OF NAME Recorded May 6, 2019
From: PICOMOLE INSTRUMENTS INC.
To: PICOMOLE INC.
Reel/Frame 049093/0506 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2015
From: CORMIER, JOHN
To: VALAISTA HEALTH INC.
Reel/Frame 035767/0811 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2015
From: VALAISTA HEALTH INC.
To: PICOMOLE INSTRUMENTS INC.
Reel/Frame 035767/0969 →
Continuity (2)
Provisional Application 62002157 · May 22, 2014
Related Publication 20150335266A1 · Nov 26, 2015